Literature DB >> 23439232

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Christina M Surawicz1, Lawrence J Brandt, David G Binion, Ashwin N Ananthakrishnan, Scott R Curry, Peter H Gilligan, Lynne V McFarland, Mark Mellow, Brian S Zuckerbraun.   

Abstract

Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439232     DOI: 10.1038/ajg.2013.4

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  476 in total

1.  Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens.

Authors:  Gillian A M Tarr; Linda Chui; Bonita E Lee; Xiao-Li Pang; Samina Ali; Alberto Nettel-Aguirre; Otto G Vanderkooi; Byron M Berenger; James Dickinson; Phillip I Tarr; Steven Drews; Judy MacDonald; Kelly Kim; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

2.  Toxin positivity and tcdB gene load in broad-spectrum Clostridium difficile infection.

Authors:  Hyeong Nyeon Kim; Hanah Kim; Hee-Won Moon; Mina Hur; Yeo-Min Yun
Journal:  Infection       Date:  2017-12-07       Impact factor: 3.553

Review 3.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

Review 4.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 5.  Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

6.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

Review 7.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

9.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 10.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.